Chardan Capital Cuts Krystal Biotech (NASDAQ:KRYS) Price Target to $216.00

Key Points

• Chardan Capital has reduced its price target for Krystal Biotech (NASDAQ:KRYS) from $219.00 to $216.00, maintaining a "buy" rating which indicates a potential upside of 48.25% from the recent closing price.
• Analysts' price targets for Krystal Biotech vary, with other firms like Guggenheim and Citigroup also lowering their targets, highlighting a consensus target price of $210.38 across multiple ratings.
• Insider selling and significant increases in institutional holdings over recent quarters show active trading trends in Krystal Biotech's stock ownership landscape.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) had its price target lowered by investment analysts at Chardan Capital from $219.00 to $216.00 in a research report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Chardan Capital's target price suggests a potential upside of 48.25% from the company's previous close.

Other analysts have also recently issued reports about the company. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Citigroup reissued a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America decreased their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $145.70 on Friday. The stock has a market cap of $4.22 billion, a PE ratio of 29.61 and a beta of 0.70. The firm has a 50-day moving average of $143.96 and a 200-day moving average of $154.67. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the transaction, the insider directly owned 1,508,056 shares of the company's stock, valued at $226,208,400. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 49,800 shares of company stock worth $7,487,943 in the last 90 days. Corporate insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group boosted its holdings in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP acquired a new stake in Krystal Biotech in the first quarter valued at approximately $29,000. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares during the period. Hantz Financial Services Inc. boosted its holdings in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after acquiring an additional 179 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of Krystal Biotech by 212.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.